FTC, DOJ Secure Record $12M HSR Penalty for Edwards/Genesis Deal Structuring
M&A counsel and corporate development teams must reassess HSR aggregation analysis: the FTC and DOJ just extracted the largest combined civil penalty ever for a failure-to-file case, holding both buyer and seller liable for splitting a single transaction to stay below the reporting threshold.
On July 13, 2026, DOJ, on behalf of the FTC, filed a complaint and proposed final judgment in D.D.C. against Edwards Lifesciences and Genesis MedTech for structuring Edwards' $115 million acquisition of JC Medical and a contemporaneous $25 million investment in Genesis as two separate transactions to avoid the then-applicable $119.5 million HSR size-of-transaction threshold. Edwards will pay a $10 million civil penalty and Genesis $2 million—the largest combined HSR failure-to-file penalty on record. The settlement also imposes a five-year prior-notification regime on Edwards for any TAVR-AR-related acquisition, a court-ordered antitrust compliance program, and ongoing inspection rights. Critically, the agencies pursued both sides of the deal, signaling that sellers bear independent HSR compliance risk. The matter follows the FTC's January 2026 injunction blocking Edwards' related $945 million JenaValve acquisition, where the undisclosed JC Medical deal was used against Edwards. Practitioners should treat any contemporaneous related-party consideration—minority investments, earnouts, licensing payments—as presumptively subject to aggregation analysis under 16 C.F.R. §§ 801.10 and 801.90, and document the analysis contemporaneously.